by the ORP. This feature highlights an NCCN study funded through the grant mechanism. TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab, in Patients With Stage IV Nonsquamous NSCLC Who Harbor a
Search Results
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Linda Farkas, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Lisa A. Gurski
one regimen to be preferable over another as initial therapy for metastatic disease. The panel also does not indicate a preference for biologic agents used as part of initial therapy (ie, bevacizumab, cetuximab, panitumumab, none). Therapy Retreatment
Alan P. Venook
proved wrong was that a drug that works well in mCRC would also be effective in the adjuvant setting. In the NSABP and AVANT studies, 3 , 4 bevacizumab did not improve outcomes in patients with stage II or III disease, nor did cetuximab in the N0147
Diane Reidy and Leonard Saltz
R . Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naíve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract] . J
Elizabeth R. Plimack and Gary R. Hudes
endothelial growth factor (VEGF)-directed therapies (sorafenib, sunitinib, pazopanib, and bevacizumab) and mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus). With such a large number of treatment options, selecting among them for a
Al B. Benson III
(Panitumumab Efficacy in Combination With mFOLFOX6 Against Bevacizumab plus mFOLFOX6 in Metastatic CRC Subjects With Wild-Type KRAS Tumors), were further assessed in secondary analyses to include extended RAS testing ( KRAS exons 2, 3, 4; NRAS exons 2, 3
Keith D. Eaton and Renato G. Martins
growth factor receptor (EGFR) to chemotherapy, 7 and the incorporation of other non-chemotherapy agents 8 all failed to improve survival and QOL. Recently, the addition of the anti–vascular endothelial growth factor (VEGF) antibody bevacizumab
Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple-Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple-negative breast cancer Institutions: University of Tennessee Cancer
Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple negative breast
Sonia Oskouei, Amy Graham Russell, Yolaine Jeune-Smith, and Ajeet Gajra
critical therapies with the potential to lower cost of care. There are 9 FDA approved therapeutic oncology biosimilars to 3 reference molecules: trastuzumab (5), bevacizumab (2) and rituximab (2), in addition to supportive care biosimilars for hematopoietic
